TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Benitec Biopharma Inc.
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

Benitec Biopharma will provide an update on its Phase 1b/2a clinical study for BB-301, a gene therapy treatment for Oculopharyngeal Muscular Dystrophy, focusing on results from six patients in Cohort 1.

Insights
GOOGL   neutral

Expected to report earnings of $2.32 per share on revenue of $99.64 billion, with a robust quality ranking


BNTC   neutral

Company is reporting ongoing clinical trial progress without indicating definitive positive or negative outcomes; presenting interim results of a Phase 1b/2a study